Mediclinic International PLC (LON:MDC) has been given an average rating of “Hold” by the eight analysts that are presently covering the firm. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is GBX 964.43 ($11.75).

A number of analysts have recently weighed in on the stock. Jefferies Group cut their price objective on shares of Mediclinic International PLC from GBX 833 ($10.15) to GBX 812 ($9.90) and set a “hold” rating on the stock in a research note on Wednesday, September 28th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 1,160 ($14.14) price objective on shares of Mediclinic International PLC in a research note on Tuesday, August 23rd. Finally, Citigroup Inc. upgraded shares of Mediclinic International PLC to a “buy” rating and increased their price objective for the stock from GBX 990 ($12.07) to GBX 1,150 ($14.02) in a research note on Tuesday, June 28th.

Shares of Mediclinic International PLC (LON:MDC) traded down 1.97% during mid-day trading on Monday, reaching GBX 896.50. 1,162,739 shares of the company’s stock traded hands. The company’s 50 day moving average is GBX 947.06 and its 200 day moving average is GBX 964.99. The company’s market cap is GBX 6.61 billion. Mediclinic International PLC has a 12-month low of GBX 794.50 and a 12-month high of GBX 1,219.00.

About Mediclinic International PLC

Mediclinic International plc, formerly Al Noor Hospitals Group plc, is a holding company. The Company operates as an international private healthcare provider. Its segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services.

Receive News & Stock Ratings for Mediclinic International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International PLC and related stocks with our FREE daily email newsletter.